DexCom is a medical device manufacturer that develops and sells continuous glucose monitoring systems used in diabetes care and metabolic health management globally. The company's product portfolio includes several CGM devices for different patient populations, ranging from its advanced G7 system to the Stelo biosensor for non-insulin-dependent patients with Type 2 diabetes and prediabetes, along with companion remote monitoring applications. The company distributes its products through direct relationships with healthcare providers including endocrinologists, physicians, and diabetes educators.
1Y: 82.29 (+41.3%) · range 54.84–92.34
entry readiness 48 · WEAK SETUP · exit proximity 0
Value area 66.74–87.00 · 40% of 120d volume overhead · moderate overhead
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.684 | Oct 30, 2026 |
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -2.17% | +2.74% | mature |
| 40d | -2.41% | +2.74% | mature |